Traws Pharma CFO Charles Nolan Parker files initial beneficial ownership statement

Traws Pharma delays annual report filing, seeks 15-day extension

Traws Pharma Inc expected to post a loss of $1.22 a share - Earnings Preview

BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold

BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients

Traws Pharma reports Phase 2 ratutrelvir study results versus Paxlovid in COVID-19 patients

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in Paxlovid®-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Inc - FDA Places Clinical Hold on Tivoxavir Marboxil Ind

Traws Pharma Inc: FDA Intends to Communicate Its Concerns Formally, Together With Suggested Mitigation Steps, by March 16

Traws Pharma initiated with a Buy at Ladenburg

Traws Pharma Completes Enrollment in Phase 2 Ratutrelvir COVID-19 Study

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma Files IND Application for Tivoxavir Marboxil Influenza Therapy

Traws Pharma Inc: Full Study Enrollment Expected in January 2026

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (Ind) Application for Influenza Therapy, and Provides Updated Results From the Ongoing Clinical Study of Ratutrelvir in Paxlovid®-Eligible and Ineligible Covid-19 Patients

Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients

Traws Pharma Inc: Ratutrelvir Shows a Differentiated Profile Versus Paxlovid™ With Fewer Adverse Events and No Viral Rebounds

Traws Pharma Inc: Final Data Analysis to Be Reported in January 2026

Traws Pharma Reports Positive Interim Clinical Data With Ratutrelvir Versus Paxlovid™, Shows Activity in Paxlovid-Ineligible Covid-19 Patients

Traws Pharma Grants Stock Options and RSUs to Executive Team